Merck sharpens cancer focus with AZ outlicensing deal
This article was originally published in Scrip
Executive Summary
Merck & Co is out-licensing the WEE1 kinase inhibitor MK-1775 to AstraZeneca to focus on its later stage oncology programs, MK-3475 and vintafolide. Deal-mad AstraZeneca is paying $50m upfront for the oral small molecule which is currently in Phase IIa studies in combination with standard-of-care therapies for P53-deficient ovarian cancer.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.